| Name | Title | Contact Details |
|---|---|---|
Garry Pairaudeau |
Chief Technology Officer | Profile |
Eileen Jennings-Brown |
Chief Information Officer | Profile |
At BioNTech we believe that every cancer patient’s treatment should be individualized. Our vision is to provide patient-specific immunotherapies worldwide.
Synlogic is a clinical-stage biotechnology company developing medicines through its proprietary approach to synthetic biology. Synlogic`s pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the second half of 2022, and additional novel drug candidates designed to treat homocystinuria (HCU) and enteric hyperoxaluria. The rapid advancement of these potential biotherapeutics, called Synthetic Biotics, has been enabled by Synlogic`s proprietary, reproducible, target-specific drug design. Synlogic uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunologic diseases. Synlogic is also working with Roche in a research collaboration focused on the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease and with Ginkgo Bioworks to include additional undisclosed preclinical assets, combining Synlogic`s approach to Synthetic Biotics with Ginkgo`s Codebase and Foundry services.
biozeen is a Allentown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mednex is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PAR Management is a Newton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.